Assessment of Thin-Layer Breast Aspirates for Immunocytochemical Evaluation of HER2 Status

Acta Cytologica

Volumn 47, Issue 6, 2003, Pages 979-984

  Bédard, Yvan C ^a,b   Pollett, Aaron F ^a,b   Leung, Stephen W ^a   O'Malley, Frances P ^a,b  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Aspiration biopsy; Breast cancer; HER 2 proto oncogene protein; Immunocytochemistry; Thin layer preparations

Indexed keywords

ANTIBODY LABELING; ANTIGEN SPECIFICITY; ARTICLE; BREAST BIOPSY; CONTROLLED STUDY; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; MEDICAL ASSESSMENT; NEEDLE BIOPSY; ONCOGENE NEU; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TISSUE FIXATION; TISSUE SECTION;

EID: 0344033745     PISSN: 00015547     EISSN: 19382650     Source Type: Journal    
DOI: 10.1159/000326671     Document Type: Article

References (29)

1. Cooke T, Reeves J, Lanigan A, Stanton P: HER2 as a prognostic and predictive marker for breast cancer. Ann Oncol (suppl) 2001;12:S23-S28
2. Schnitt SJ: Breast cancer in the 21st century: Neu opportunities and neu challenges. Mod Pathol 2001;14:213-218
3. Horton J: Her2 and trastuzumab in breast cancer. Cancer Control 2001;8:103-110
4. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-182
5. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-712
6. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792
7. Tetu B, Brisson J: Prognostic significance of HER-2/neu oncoprotein expression in node-positive breast cancer: The influence of the pattern of immunostaining and adjuvant therapy. Cancer 1994;73:2359-2365
8. Tubbs RR, Pettay JD, Roche PC, Stoler MH, Jenkins RB, Grogan TM: Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: Apparent immunohistochemical false-positives do not get the message. J Clin Oncol 2001;19:2714-2721
9. Bédard YC, Pollett AF: Breast fine-needle aspiration: A comparison of ThinPrep and conventional smears. Am J Clin Pathol 1999;111:523-527
10. O'Malley FP, Parkes R, Latta E, Tjan S, Zadro T, Mueller R, Arneson N, Blackstein M, Andrulis I: Comparison of HER2/neu status assessed by quantitative polymerase chain reaction and immunohistochemistry. Am J Clin Pathol 2001;115:504-511
11. Neubauer A, Neubauer B, He M, Effert P, Iglehart D, Frye RA, Liu E: Analysis of gene amplification in archival tissue by differential polymerase chain reaction. Oncogene 1992;7:1019-1025
12. Allred DC, Clark GM, Elledge R, Fuqua SA, Brown RW, Chamness GC, Osborne CK, McGuire WL: Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 1993;85:200-206
13. Allred DC, Harvey JM, Berardo M, Clark GM: Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998;11:155-168
14. Leung SW, Bédard YC: Immunocytochemical staining on ThinPrep processed smears. Mod Pathol 1996;9:304-306
15. Pollett A, Bédard YC, Li SQ, Rohan T, Kandel R: Correlation of p53 mutations in ThinPrep-processed fine needle breast aspirates with surgically resected breast cancers. Mod Pathol 2000;13:1173-1179
16. Schnitt SJ, Jacobs TW: Current status of HER2 testing: Caught between a rock and a hard place. Am J Clin Pathol 2001;116:806-810
17. Andrulis IL, Bull SB, Blackstein ME, Sutherland D, Mak C, Sidlofsky S, Pritzker KP, Hartwick RW, Hanna W, Lickley L, Wilkinson R, Qizilbash A, Ambus U, Lipa M, Weizel H, Katz A, Baida M, Mariz S, Stoik G, Dacamara P, Strongitharm D, Geddie W, McCready D: neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer: Toronto Breast Cancer Study Group. J Clin Oncol 1998;16:1340-1349
18. O'Malley FP, Thomson T, Julian JA, Cosby R, Have C, Dubois S, Whelan T, Gelmon K, Andrulis I: Comparison of HER2/neu status evaluated by FISH and two methods of quantitative PCR (abstr). Mod Pathol 2003;16:42A
19. Nizzoli R, Bozzetti C, Crafa P, Naldi N, Guazzi A, Di Blasio B, Camisa R, Cascinu S: Immunocytochemical evaluation of HER-2/neu on fine-needle aspirates from primary breast carcinomas. Diagn Cytopathol 2003;28:142-146
20. Allred DC, Clark GM, Tandon AK, Molina R, Tormey DC, Osborne CK, Gilchrist KW, Mansour EG, Abeloff M, Eudey L: HER-2/neu in node-negative breast cancer: Prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol 1992;10:599-605
21. Masood S, Bui MM: Assessment of Her-2/neu overexpression in primary breast cancers and their metastatic lesions: An immunohistochemical study. Ann Clin Lab Sci 2000;30:259-265
22. Vang R, Coley LD, Harrison WR, Reese T, Abrams J: Immunohistochemical determination of HER-2/neu expression in invasive breast carcinoma. Am J Clin Pathol 2000;113:669-674
23. Gancberg D, Lespagnard L, Rouas G, Paesmans M, Piccart M, Di Leo A, Nogaret JM, Hertens D, Verhest A, Larsimont D: Sensitivity of HER-2/neu antibodies in archival tissue samples of invasive breast carcinomas: Correlation with oncogene amplification in 160 cases. Am J Clin Pathol 2000;113:675-682
24. Troncone G, Panico L, Vetrani A, de Divitiis B, Zeppa P, Fulciniti F, Pettinato G, Palombini L: c-erbB-2 expression in FNAB smears and matched surgical specimens of breast cancer. Diagn Cytopathol 1996;14:135-139
25. Solomides CC, Zimmerman R, Bibbo M: Semiquantitative assessment of c-erbB-2 (HER-2) status in cytology specimens and tissue sections from breast carcinoma. Analyt Quant Cytol Histol 1999;21:121-125
26. Penault-Llorca F, Adelaide J, Houvenaeghel G, Hassoun J, Birnbaum D, Jacquemier J: Optimization of immunohistochemical detection of ERBB2 in human breast cancer: Impact of fixation. J Pathol 1994;173:65-75
27. Corkill ME, Katz R: Immunocytochemical staining of c-erb B-2 oncogene in fine-needle aspirates of breast carcinoma: A comparison with tissue sections and other breast cancer prognostic factors. Diagn Cytopathol 1994;11:250-254
28. Tiniakos DG, Robinson KB, Greenwood H, Cullen P, Cook AI, Horne CH, Angus B: c-erb B-2 and p53 expression in breast cancer fine needle aspirates. Cytopathology 1996;7:178-186
29. Thomson TA, Hayes MM, Spinelli JJ, Hilland E, Sawrenko C, Phillips D, Dupuis B, Parker RL: HER-2/neu in breast cancer: Interobserver variability and performance of immunohistochemistry with 4 antibodies compared with fluorescent in situ hybridization. Mod Pathol 2001;14:1079-1086